Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.338, issue.18 ,
DOI : 10.1056/NEJM199804303381805
Sunitinib versus Interferon Alfa in Metastatic Renal?Cell Carcinoma, N Engl J Med N Engl J Med, vol.338356, issue.2, pp.115-139, 1998. ,
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007. ,
DOI : 10.1056/NEJMoa060655
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007. ,
DOI : 10.1056/NEJMoa066838
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer, Cancer, vol.23, issue.4, pp.776-83, 2009. ,
DOI : 10.1002/cncr.24051
Treatment and overall survival (OS) in metastatic renal cell carcinoma (mRCC): A Swedish population-based study (2000???2008)., Journal of Clinical Oncology, vol.30, issue.5_suppl, p.389, 2012. ,
DOI : 10.1200/jco.2012.30.5_suppl.389
Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.4660, 2011. ,
DOI : 10.1200/jco.2011.29.15_suppl.4660
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor?Targeted Agents: Results From a Large, Multicenter Study An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer, J Clin Oncol Eur J Cancer, vol.2748, pp.3171-3177, 2009. ,
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib, British Journal of Cancer, vol.17, issue.12, pp.1811-1814, 2011. ,
DOI : 10.1038/sj.bjc.6604456
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma, Cancer, vol.28, issue.18 suppl, pp.1868-76, 2012. ,
DOI : 10.1002/cncr.26429
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial, The Lancet Oncology, vol.12, issue.7, pp.673-80, 2011. ,
DOI : 10.1016/S1470-2045(11)70124-3
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow?up, Ann Oncol, vol.23, 2012. ,
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-85, 2010. ,
DOI : 10.1200/JCO.2009.23.9764
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1940, 2011. ,
DOI : 10.1016/S0140-6736(11)61613-9
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma, Journal of Clinical Oncology, vol.30, issue.14, pp.1678-85, 2012. ,
DOI : 10.1200/JCO.2011.35.3524
Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-65, 2012. ,
DOI : 10.1056/NEJMoa1200694
Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012. ,
DOI : 10.1056/NEJMoa1200690